Author

K. Shcherbina

Harvard University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1 Research Focus:differential expression· 1 Organism:human· 1 Assay:metabolomics· 1 Organism:mouse· 1

Frequent Co-Authors

E. Gardner· 2 shared R. NovakiD· 2 shared A. Dinis· 1 shared A. Kuelker· 1 shared A. Sesay· 1 shared Anish VasaniD· 1 shared B. Charrez· 1 shared C. J. Hinshaw· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

E. Gardner

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Identification of pharmacological inducers of a reversible hypometabolic state for whole organ preservation

M. M. Sperry, B. Charrez, H. Fotowat, E. Gardner, K. Pilobello, Z. Izadifar, T. Lin, A. Kuelker, S. Kaki, M. Lewandowski, S. Lightbown, R. Martinez, S. Marquez, J. Moore, M. Plaza-Oliver, , D. E. Ingber

The paper identifies SNC80 as a drug that reversibly slows metabolism in Xenopus and demonstrates its cross-species applicability in human organs-on-chips and porcine organs.

eLife · Sep 24, 2024Peer-reviewedBioengineering

Target-agnostic discovery of Rett Syndrome therapeutics by coupling computational network analysis and CRISPR-enabled in vivo disease modeling

R. Novak, Tiffany Lin, S. Kaushal, Megan M. Sperry, Frédéric Vigneault, E. Gardner, Sahil Loomba, K. Shcherbina, Vishal Keshari, A. Dinis, Anish Vasan, V. Chandrasekhar, Takako Takeda, Jerrold R. Turner, Michael G. Levin, Donald E. Ingber

This paper identifies vorinostat as a potential repurposed therapy for Rett syndrome by combining computational network analysis with CRISPR-edited Xenopus models, showing efficacy across multiple organ systems.

bioRxiv · Mar 20, 2022 · PreprintNeuroscience